Baidu
map

J Thromb Haemost:癌症与脑静脉血栓形成风险!

2017-11-13 xing.T MedSci原创

该研究的结果表明癌症是CVT的较强的危险因素,特别是血液系统癌症患者在癌症诊断的第一年内。

癌症是下肢静脉血栓形成和肺栓塞已知的危险因素。尚未有对照研究对癌症患者脑静脉血栓(CVT)的风险进行评估。近日,血栓和凝血疾病权威杂志Journal of Thrombosis and Haemostasis上发表了一篇研究文章,研究人员旨在评估癌症是否是CVT的危险因素。

在这项病例对照研究中,研究人员评估了1987-2015年期间三所教学医院连续就诊的成年CVT患者以及来自于荷兰MEGA研究(静脉血栓形成危险因素的多重环境和遗传评估)的对照者。研究人员调整了年龄、性别和口服避孕药,并根据癌症类型和诊断癌症以来的时间进行分层。

研究人员纳入了594例CVT患者和6278例对照组。总共有53例(8.9%)患者和160例(2.5%)对照者有癌症病史。相比于比对照者,CVT患者更年轻(中位数为42 vs. 48岁),女性更常见(68% vs. 54%),口服避孕药的比例更高(55% vs. 23%)。与非癌症患者相比,癌症患者的CVT风险增加(校正后的比值比[aOR]为4.86,95%可信区间[CI]为3.46-6.81)。患有血液系统癌症的患者具有较高的CVT风险(aOR为25.14,95%CI为11.64-54.30),与具体实体癌症的患者相比(aOR为3.07,95%CI为2.03-4.65)。在诊断癌症后的第一年,这种关联性最强(血液系统肿瘤aOR为85.57,95%CI为19.70-371.69;实体肿瘤aOR为10.50,95%CI为5.40-20.42)。

该研究的结果表明癌症是CVT的较强的危险因素,特别是血液系统癌症患者在癌症诊断的第一年内。

原始出处:

S. M. Silvis,et al. Cancer and risk of cerebral venous thrombosis: a case-control study. Journal of Thrombosis and Haemostasis.2017. http://onlinelibrary.wiley.com/doi/10.1111/jth.13903/full

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1955326, encodeId=05521955326eb, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue May 22 14:07:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697574, encodeId=afc2169e574f1, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 29 23:07:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008316, encodeId=2db9200831682, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Jul 26 15:07:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483258, encodeId=ec0314832587f, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Wed Nov 15 09:07:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
    2018-05-22 xue8602
  2. [GetPortalCommentsPageByObjectIdResponse(id=1955326, encodeId=05521955326eb, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue May 22 14:07:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697574, encodeId=afc2169e574f1, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 29 23:07:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008316, encodeId=2db9200831682, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Jul 26 15:07:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483258, encodeId=ec0314832587f, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Wed Nov 15 09:07:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
    2017-11-29 fusion
  3. [GetPortalCommentsPageByObjectIdResponse(id=1955326, encodeId=05521955326eb, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue May 22 14:07:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697574, encodeId=afc2169e574f1, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 29 23:07:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008316, encodeId=2db9200831682, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Jul 26 15:07:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483258, encodeId=ec0314832587f, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Wed Nov 15 09:07:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
    2018-07-26 changfy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1955326, encodeId=05521955326eb, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue May 22 14:07:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697574, encodeId=afc2169e574f1, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 29 23:07:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008316, encodeId=2db9200831682, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Jul 26 15:07:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483258, encodeId=ec0314832587f, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Wed Nov 15 09:07:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]

相关资讯

J Biol Chem:如何有效增强机体免疫功能来有效抵御癌症?

近日,一项刊登在国际杂志《Journal of Biological Chemistry》上的研究报告中,来自约克大学的研究人员通过研究阐明了如何增强机体免疫系统来有效抵御癌症;文章中,研究者发现,健康细胞能利用一种特技来抑制机体免疫反应被过度抑制,相关研究或有望改善研究人员对癌症免疫疗法的使用和管理。

Nature:防止癌症复发不是梦,科学家已找到耐药癌细胞共同弱点

美国加州大学旧金山分校的研究人员发现了一个基因上的弱点,可以让肿瘤医生消灭多种抗药性类型的癌症。近期在线发表在Nature上的这项发现表明,如果能在人类患者身上得到证实,就有可能找到一种有效预防癌症复发的新方法。

PNAS:科学家成功吸引大批“自然杀伤”细胞,癌细胞无处可逃!

卢森堡研究所的研究小组通过研究黑色素瘤,一种高度恶性的皮肤癌揭示了一种机制,通过这种机制可以切换到一个免疫支持的免疫抑制环境。他们发现如果细胞内循环过程自噬产生细胞因子,就会吸引自然杀伤细胞。自然杀伤细胞的大规模招募可以杀死癌细胞,使肿瘤缩小。

癌症不喜欢亚裔人群?全球癌症数据告诉你真相

中国是世界第一人口大国,随着人口老龄化的加重,未来的抗癌斗争必将越来越惨烈。目前中国癌症死亡率发病率比维持在0.6-0.7,也就是60%-70%的癌症患者最终都没有治愈。那么放眼全球,中国是什么水平呢?

Nature Biomedical Engineering:一种新策略打尽所有癌症相关DNA、RNA和蛋白质

今天著名学术期刊《Nature Biomedical Engineering》发文报道,一种全新的治疗策略几乎横扫所有类型癌细胞。

JAMA Inter Med:挪威科学家确定Warfarin阻凝剂预防癌症有奇效,有望成为癌症疫苗

一项新的研究表示,华法令可以降低癌症发展的风险。华法令阻凝剂是一种用于降低心脏病发作或中风风险的药物。然而,在这项新的研究中,来自挪威的研究人员们找到证据证明,这种药物也可能有助于减少患癌症的风险,尤其是50岁以上的人群。研究报告发表于JAMA内科杂志中。

Baidu
map
Baidu
map
Baidu
map